Skip navigation
中文
English
DSpace
CRIS
首頁
單位
研究人員
研究成果檢索
分類瀏覽
單位
研究人員
研究成果檢索
學術出版
幫助
登入
中文
English
NTU Scholars
國立臺灣大學
/
醫學院附設醫院 (臺大醫院)
/
癌醫中心分院
/
腫瘤內科部-癌醫中心分院
BIN-CHI LIAO
研究人員網路
瀏覽統計
Email 通知
RSS Feed
簡歷
研究成果
10
計畫
3
研究成果
(其他)
全部
期刊文章
回顧型論文
圖書及章節
其他
顯示/隱藏過濾條件
依作者
10
bin-chi liao
10
chih-hsin yang
6
chia-chi lin
2
jih-hsiang lee
2
liao b.-c;lin c.-c;chih-hsin yang
1
chen y.-m.
1
chih-hsin yang;liao b.-c
1
chiu c.-h.
1
chou t.-y.
1
griesing s.
.
下一頁 >
主題
7
[sdgs]sdg3
1
2 [[2 (isopropylsulfonyl)phenyl]amino] 4 [[2 methoxy 4 [4 (4 methyl 1 piperazinyl) 1 piperidinyl]phenyl]amino] 1,3,5 triazine; 6 amino 5 [1 (2,6 dichloro 3 fluorophenyl)ethoxy] n [4 (4 methyl 1 piperazinylcarbonyl)phenyl] 3 pyridazinecarboxamide; alectinib; anaplastic lymphoma kinase; anaplastic lymphoma kinase inhibitor; cep 37440; ceritinib; crizotinib; entrectinib; ganetespib; luminespib; onalespib; pf 06463922; retaspimycin; tsr 011; unclassified drug; [2 [[5 chloro 2 [[4 [4 (dimethylamino) 1 piperidinyl] 2 methoxyphenyl]amino] 4 pyrimidinyl]amino]phenyl]dimethylphosphine oxide; advanced cancer; cancer resistance; cancer therapy; central nervous system metastasis; fluorescence in situ hybridization; food and drug administration; human; japan; non small cell lung cancer; priority journal; review; treatment outcome
1
afatinib; bemcentinib; buparlisib; capmatinib; crizotinib; dacomitinib; dubermatinib; emibetuzumab; epidermal growth factor receptor; epidermal growth factor receptor 2; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; kelch like ech associated protein 1; luminespib; mammalian target of rapamycin; mitogen activated protein kinase; necitumumab; osimertinib; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; programmed death 1 ligand 1; protein tyrosine kinase; raf protein; ras protein; savolitinib; selumetinib; tepotinib; tivantinib; trastuzumab emtansine; unindexed drug; akt signaling; akt/mtor signaling; cancer combination chemotherapy; cancer immunotherapy; cancer resistance; cancer staging; cell transformation; clinical trial (topic); decreased appetite; dermatitis; diarrhea; epithelial mesenchymal transition; fatigue; fever; fluorescence in situ hybridization; gene dosage; gene mutation; gene overexpression; human; hypoalbuminemia; immunohistochemistry; liquid biopsy; neutropenia; next generation sequencing; non small cell lung cancer; nonhuman; peripheral edema; pi3k/akt signaling; pneumonia; priority journal; progression free survival; review; stomatitis; treatment duration; treatment response
1
afatinib; bevacizumab; carboplatin; cisplatin; dacomitinib; docetaxel; epidermal growth factor receptor; erlotinib; gefitinib; gemcitabine; hydroxychloroquine; olaparib; paclitaxel; pemetrexed; acne; anemia; anorexia; cancer combination chemotherapy; cancer survival; dermatitis; diarrhea; drug efficacy; drug eruption; drug safety; exon; fatigue; gene mutation; gene sequence; histology; human; interstitial lung disease; lung adenocarcinoma; lung non small cell cancer; medline; monotherapy; neutropenia; overall survival; paronychia; phase 2 clinical trial (topic); phase 3 clinical trial (topic); polymerase chain reaction; progression free survival; quality of life; rash; review; side effect; survival rate; survival time; treatment failure; treatment response; adenocarcinoma; antineoplastic agents; carcinoma, non-small-cell lung; clinical trials, phase iii as topic; female; humans; lung neoplasms; male; mutation; protein kinase inhibitors; receptor, epidermal growth factor; risk factors; sex factors; treatment outcome
1
afatinib; cetuximab; cytotoxic agent; epidermal growth factor receptor; erlotinib; gefitinib; naquotinib; nazartinib; olmutinib; osimertinib; protein tyrosine kinase inhibitor; rociletinib; antineoplastic agent; epidermal growth factor receptor; protein kinase inhibitor; scatter factor receptor; cancer chemotherapy; cancer combination chemotherapy; cancer survival; cancer therapy; disease course; gene amplification; gene mutation; human; information retrieval; liquid biopsy; lung biopsy; medline; non small cell lung cancer; priority journal; review; tumor biopsy; algorithm; disease exacerbation; disease management; drug development; genetics; lung tumor; molecularly targeted therapy; mutation; non small cell lung cancer; pathology; treatment outcome; algorithms; antineoplastic agents; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; disease management; disease progression; drug discovery; gene amplification; humans; lung neoplasms; molecular targeted therapy; mutation; protein kinase inhibitors; proto-oncogene proteins c-met; receptor, epidermal growth factor; treatment outcome
1
alectinib; anaplastic lymphoma kinase inhibitor; atezolizumab; azd 3759; ceritinib; crizotinib; epidermal growth factor receptor; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; nivolumab; osimertinib; pembrolizumab; unclassified drug; abc transporter subfamily b; antineoplastic agent; epidermal growth factor receptor; protein kinase inhibitor; brain metastasis; brain radiation; cancer chemotherapy; cancer patient; human; local therapy; medline; non small cell lung cancer; prospective study; review; systemic therapy; antagonists and inhibitors; brain tumor; clinical trial (topic); drug resistance; genetics; lung tumor; metabolism; mutation; non small cell lung cancer; pathology; secondary; antineoplastic agents; atp binding cassette transporter, sub-family b; brain neoplasms; carcinoma, non-small-cell lung; clinical trials as topic; drug resistance, neoplasm; humans; lung neoplasms; mutation; protein kinase inhibitors; receptor, epidermal growth factor
依日期
10
2000 - 2024
依類型
4
review
3
review
1
editorial
1
note
1
other
全文
10
no fulltext
關閉過濾條件
第 1 到 10 筆結果,共 10 筆。
公開日期
標題
作者
來源出版物
scopus
WOS
全文
1
2016
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
BIN-CHI LIAO
; CHIA-CHI LIN
; JIH-HSIANG LEE
; CHIH-HSIN YANG
Journal of Biomedical Science
43
37
2
2015
Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
BIN-CHI LIAO
; CHIA-CHI LIN
; JIN-YUAN SHIH
; CHIH-HSIN YANG
Therapeutic Advances in Medical Oncology
16
16
3
2018
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
BIN-CHI LIAO
; CHIA-CHI LIN
; CHIH-HSIN YANG
Expert Opinion on Pharmacotherapy
5
5
4
2019
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
BIN-CHI LIAO
; Griesing S.; CHIH-HSIN YANG
Therapeutic Advances in Medical Oncology
27
25
5
2017
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
BIN-CHI LIAO
; Chia-Chi Lin
; JIH-HSIANG LEE
; CHIH-HSIN YANG
Lung Cancer
38
35
6
2017
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
BIN-CHI LIAO
; CHIA-CHI LIN
; CHIH-HSIN YANG
Current Oncology Reports
19
19
7
2021
Lung Cancer in Republic of China
Luo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; CHIH-HSIN YANG
; BIN-CHI LIAO
; Hsia T.-C.; Chen Y.-M.
Journal of Thoracic Oncology
33
26
8
2012
Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study
BIN-CHI LIAO
; CHIH-HSIN YANG
Translational Lung Cancer Research
0
0
9
2013
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
BIN-CHI LIAO
; CHIA-CHI LIN
; CHIH-HSIN YANG
Drugs
15
16
10
2021
Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC
BIN-CHI LIAO
; CHIH-HSIN YANG
Journal of Thoracic Oncology
0
0
申請連結研究人員資料
以 ORCID 登入申請連結此個人資料
ORCID Login
Contact via feedback form
若您要聯絡網站管理員,請點選以下按鈕